Adaptive Biotechnologies GAAP EPS of -$0.25 misses by $0.12, revenue of $71.55M beats by $6.1M
Seeking Alpha News (Wed, 29-Jul 4:38 PM ET)
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 29-Jul 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 29-Jul 10:00 AM ET)
Adaptive Biotechnologies Q2 2026 Earnings Preview
Seeking Alpha News (Tue, 28-Jul 5:35 PM ET)
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Globe Newswire (Thu, 9-Jul 4:05 PM ET)
Adaptive Biotechnologies Boosts Flexibility with $300 Million Upsized Convertible Notes Offering
Market Chameleon (Wed, 17-Jun 4:57 AM ET)
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
Globe Newswire (Wed, 17-Jun 6:00 AM ET)
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
Globe Newswire (Mon, 15-Jun 4:10 PM ET)
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
Globe Newswire (Mon, 15-Jun 4:05 PM ET)
Globe Newswire (Fri, 29-May 7:30 AM ET)
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Adaptive Biotechnologies trades on the NASDAQ stock market under the symbol ADPT.
As of July 29, 2026, ADPT stock price climbed to $22.56 with 2,671,666 million shares trading.
ADPT has a beta of 0.47, meaning it tends to be less sensitive to market movements. ADPT has a correlation of 0.01 to the broad based SPY ETF.
ADPT has a market cap of $3.61 billion. This is considered a Mid Cap stock.
Last quarter Adaptive Biotechnologies reported $71 million in Revenue and -$.13 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.03.
In the last 3 years, ADPT traded as high as $23.15 and as low as $2.28.
The top ETF exchange traded funds that ADPT belongs to (by Net Assets): VTI, IWM, ARKG, VB, IWO.
ADPT has outperformed the market in the last year with a price return of +112.6% while the SPY ETF gained +15.7%. ADPT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +60.7% and +5.3%, respectively, while the SPY returned +2.8% and -3.0%, respectively.
ADPT support price is $21.59 and resistance is $23.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADPT shares will trade within this expected range on the day.